How many insider trades does FilingIQ track for AKBA?

FilingIQ tracks 354 Form 4 insider transactions for AKBA (Akebia Therapeutics, Inc.), covering filings from Dec 23, 2014 onwards. 2 of those were filed in the last 90 days.

Are AKBA insiders net buyers or net sellers?

Across the full Form 4 history for AKBA, 8 transactions (2%) were open-market purchases and 142 (40%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does AKBA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is AKBA in?

Akebia Therapeutics, Inc. (AKBA) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $321.09M.

AKBA insider trading

NasdaqCM Healthcare

Akebia Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

354

Last 90 days

Buys / sells

2% / 40%

Market cap

$321.09M

About Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Company website: www.akebia.com

AKBA insider activity at a glance

FilingIQ has scored 354 insider transactions for AKBA since Dec 23, 2014. The most recent filing in our index is dated Apr 1, 2026.

Across the full history, 8 open-market purchases and 142 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on AKBA insider trades is 59.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live AKBA trades on FilingIQ Raw filings on SEC EDGAR

Latest AKBA Form 4 filings

Dahan Michel SVP, Chief Operating Officer

S May 25, 2023

Spellman David A SVP, CFO and Treasurer

S May 16, 2023

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for AKBA?: FilingIQ tracks 354 Form 4 insider transactions for AKBA (Akebia Therapeutics, Inc.), covering filings from Dec 23, 2014 onwards. 2 of those were filed in the last 90 days.
Are AKBA insiders net buyers or net sellers?: Across the full Form 4 history for AKBA, 8 transactions (2%) were open-market purchases and 142 (40%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does AKBA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is AKBA in?: Akebia Therapeutics, Inc. (AKBA) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $321.09M.

Methodology & sources

Every AKBA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.